logo

ALLK(Delisted)

AllakosยทNASDAQ
--
--(--)

ALLK Profile

Allakos Inc.

A clinical stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases

--
--
07/19/2018
NASDAQ Stock Exchange
61
12-31
Common stock
149 Commonwealth Dr Suite 1090, Menlo Park, California 94025
--
Allakos Inc., was incorporated in Delaware in March 2012. The company is a clinical-stage biotechnology company that develops therapies for immunomodulatory receptors present on immune effector cells associated with allergies, inflammation and proliferative diseases. AK006 targets Siglec-6, an inhibitory receptor selectively expressed on mast cells, a widely distributed white blood cell in the body that plays a central role in the inflammatory response.